Empreses emergents
2016
BIOPROGNOS SLAnàlisis de sang innovadores per a la detecció precoç i el maneig precís del càncer. Proves d'algoritmes d'activitat de la malaltia amb biomarcadors múltiples (MBDAA) disponibles per a diversos tipus de càncer.
Adreça
Carrer de Benet Mateu 40, 08034 Barcelona, Espanya
Dades financeres
Propietat CERCA
Àrees d'estat i deeptech
Estat de l'empresa i àrees de tecnologia profunda de l'empresaEstat de l'empresa
Àrea DeepTech
Informació sobre la spin-off
Descripció de l'empresa
Mission
To improve clinical outcomes and quality of life for cancer, by developing innovative, non-invasive, accurate, and cost-effective diagnostics solutions.
Vision
To be the top reference worldwide cancer diagnostics company that allows people to enjoy better health.
To improve clinical outcomes and quality of life for cancer, by developing innovative, non-invasive, accurate, and cost-effective diagnostics solutions.
Vision
To be the top reference worldwide cancer diagnostics company that allows people to enjoy better health.
Descripció del producte
Multiple Biomarkers Disease Activity Algorithms (MBDAAs)
Biomarkers are making their way into investigation and are producing an enormous amount of information: With the rapid advances in genomic and proteomic technology, the discovery of useful biomarkers has arisen to unravel the unique signatures of cancer cells, enabling investigators to pose scientific questions and address problems that, until recently, were inconceivable.
This has shifted the focus on biomarker-based disease detection from one biomarker to a panel of biomarkers, for which we develop Multiple Biomarkers Disease Activity Algorithms (MBDAAs) as standard-of-care replacement for diagnosis, confirmatory diagnostic ―as an adjunct to suspicious image procedures findings, in order to reduce the number of unnecessary tissue biopsies that patients have to undergo―, or as complementary criteria.
Biomarkers are making their way into investigation and are producing an enormous amount of information: With the rapid advances in genomic and proteomic technology, the discovery of useful biomarkers has arisen to unravel the unique signatures of cancer cells, enabling investigators to pose scientific questions and address problems that, until recently, were inconceivable.
This has shifted the focus on biomarker-based disease detection from one biomarker to a panel of biomarkers, for which we develop Multiple Biomarkers Disease Activity Algorithms (MBDAAs) as standard-of-care replacement for diagnosis, confirmatory diagnostic ―as an adjunct to suspicious image procedures findings, in order to reduce the number of unnecessary tissue biopsies that patients have to undergo―, or as complementary criteria.